{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:15:58Z","timestamp":1789049758361,"version":"build-2803163510"},"posted":{"date-parts":[[2026,9,7]]},"group-title":"Biochemistry","reference-count":30,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01HL127155"],"award-info":[{"award-number":["R01HL127155"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R15HL154071"],"award-info":[{"award-number":["R15HL154071"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100021274","name":"Joseph Drown Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100021274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Lipase maturation factor 1 (LMF1) is a chaperone for lipoprotein lipase (LPL) and critically required for the enzyme to attain lipase activity. LMF1 has been identified as a canonical gene affected in Familial Chylomicronemia Syndrome (FCS) and it has also been extensively analyzed in Multifactorial Chylomicronemia Syndrome (MCS), the polygenic form of severe hypertriglyceridemia (hTG). While recent genetic studies resulted in an explosion in the number of hTG-associated LMF1 variants in different populations, their functional significance remains largely unknown. Here, we present a second-generation LMF1 activity assay allowing the streamlined quantitative functional analysis of LMF1 variants. The assay is based on the reconstitution of lipase maturation in transfected LMF1-deficient cells and fluorescence-based measurement of LPL activity in the culture medium. The use of Gaussia luciferase (GLuc)-LMF1 fusion constructs allows the assessment of LMF1 protein expression and the calculation of LMF1 specific activity. Several variants previously reported as neutral resulted in loss of LMF1 function in the new assay demonstrating increased sensitivity to detect variants of modest effect sizes. Furthermore, the functional analysis of 14 hTG-associated missense mutations identified 12 loss-of-function (LOF) variants. To gain initial insights into the structural determinants of LMF1 function, we analyzed the domain distribution of 73 hTG-associated missense variants and identified Loop C as a critical region in lipase maturation. In conclusion, we developed a simple, non-radioactive and sensitive quantitative assay of LMF1 activity to facilitate the functional analysis of hyperlipidemia-associated genetic variants and structure-function studies.<\/jats:p>","DOI":"10.64898\/2026.09.03.749245","type":"posted-content","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:25:13Z","timestamp":1788816313000},"source":"Crossref","is-referenced-by-count":0,"title":["Functional characterization of hypertriglyceridemia-associated mutations in Lipase Maturation Factor 1 by a second-generation activity assay"],"prefix":"10.64898","author":[{"given":"Candy","family":"Bedoya","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmis","family":"Rejali","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xanden","family":"McCleary","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Green","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Frost","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Malloy","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive R.","family":"Pullinger","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kane","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"P\u00e9terfy","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026091006550589000_2026.09.03.749245v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2007.24"},{"key":"2026091006550589000_2026.09.03.749245v1.2","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201797379"},{"key":"2026091006550589000_2026.09.03.749245v1.3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of Hypertriglyceridemia","volume":"11","year":"2020","journal-title":"Front Endocrinol (Lausanne"},{"key":"2026091006550589000_2026.09.03.749245v1.4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04064-3"},{"key":"2026091006550589000_2026.09.03.749245v1.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003062"},{"key":"2026091006550589000_2026.09.03.749245v1.7","first-page":"10","article-title":"Genetic Variants Associated with Severe Hypertriglyceridemia: LPL, APOC2, APOA5, GPIHBP1, LMF1, and APOE","volume":"51","year":"2023","journal-title":"Turk Kardiyol Dern Ars"},{"key":"2026091006550589000_2026.09.03.749245v1.8","doi-asserted-by":"crossref","first-page":"101365","DOI":"10.1016\/j.gim.2025.101365","article-title":"Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: Novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society","volume":"27","year":"2025","journal-title":"Genet Med"},{"key":"2026091006550589000_2026.09.03.749245v1.9","doi-asserted-by":"crossref","first-page":"103445","DOI":"10.1016\/j.gimo.2025.103445","article-title":"Rare variant genetic landscape of familial chylomicronemia syndrome (FCS) in the United Kingdom","volume":"3","year":"2025","journal-title":"Genet Med Open"},{"key":"2026091006550589000_2026.09.03.749245v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.11.007"},{"key":"2026091006550589000_2026.09.03.749245v1.11","first-page":"100576","article-title":"Genetic and functional studies of the LMF1 gene in Thai patients with severe hypertriglyceridemia","volume":"23","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"2026091006550589000_2026.09.03.749245v1.12","doi-asserted-by":"crossref","first-page":"e1074","DOI":"10.1016\/j.jacl.2024.08.006","article-title":"Genetic variants in triglyceride metabolism genes among individuals with hypertriglyceridemia in Colombia","volume":"18","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jacl.2018.06.018","article-title":"New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia","volume":"12","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.14","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M900196-JLR200"},{"key":"2026091006550589000_2026.09.03.749245v1.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2012.02516.x"},{"key":"2026091006550589000_2026.09.03.749245v1.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0594"},{"key":"2026091006550589000_2026.09.03.749245v1.17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacl.2024.10.004","article-title":"Identification and functional analysis of novel homozygous LMF1 variants in severe hypertriglyceridemia","volume":"19","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl515"},{"key":"2026091006550589000_2026.09.03.749245v1.19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.chemphyslip.2016.05.007","article-title":"Synthesis and evaluation of fluorogenic triglycerides as lipase assay substrates","volume":"198","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"2026091006550589000_2026.09.03.749245v1.20","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.D010744"},{"key":"2026091006550589000_2026.09.03.749245v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00803-9"},{"key":"2026091006550589000_2026.09.03.749245v1.22","unstructured":"Kennedy, B . 2024. ClassificationThresholdTuner: A Python library for optimizing binary classification thresholds. In. GitHub."},{"key":"2026091006550589000_2026.09.03.749245v1.23","first-page":"81","article-title":"Determining lipoprotein lipase and hepatic lipase activity using radiolabeled substrates","volume":"109","year":"1999","journal-title":"Methods Mol Biol"},{"key":"2026091006550589000_2026.09.03.749245v1.24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacl.2017.01.003","article-title":"Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing","volume":"11","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.03.093"},{"key":"2026091006550589000_2026.09.03.749245v1.26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jacl.2018.07.008","article-title":"Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia","volume":"12","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jacl.2020.09.004","article-title":"Involvement of a homozygous exon 6 deletion of LMF1 gene in intermittent severe hypertriglyceridemia","volume":"14","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOL.0000000000001048","article-title":"Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait","volume":"37","year":"2026","journal-title":"Curr Opin Lipidol"},{"key":"2026091006550589000_2026.09.03.749245v1.29","doi-asserted-by":"crossref","unstructured":"Berberich, A. J. , A. M. Ouedraogo , S. Z. Shariff , R. A. Hegele , and K. K. Clemens . (2021) Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study. Lipids Health Dis 20: 98.","DOI":"10.1186\/s12944-021-01517-6"},{"key":"2026091006550589000_2026.09.03.749245v1.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.111.960864"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.03.749245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:55:19Z","timestamp":1789048519000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.03.749245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.64898\/2026.09.03.749245","relation":{},"subject":[],"published":{"date-parts":[[2026,9,7]]},"subtype":"preprint"}}